Effects of Angiotensin II Receptor Blockers on Ventricular Hypertrophy in Hypertrophic Cardiomyopathy: A Meta-Analysis of Randomized Controlled Trials
- 6 January 2021
- journal article
- review article
- Published by Springer Science and Business Media LLC in Cardiovascular Drugs and Therapy
- Vol. 36 (2), 371-378
- https://doi.org/10.1007/s10557-020-07118-2
Abstract
Purpose Animal studies have suggested that angiotensin II receptor blockers (ARBs) can attenuate or reverse the progression of hypertrophic cardiomyopathy, while clinical studies yielded conflicting results. We sought to conduct a meta-analysis to investigate the effect of ARBs in patients with hypertrophic cardiomyopathy. Methods PubMed and EMBASE databases were searched through June 2020. Only randomized controlled trials (RCTs) were included, and each study’s quality was assessed using the Jadad scale. The primary outcome was left ventricular mass reduction, and the secondary outcome was the change in left ventricular ejection fraction (LVEF). Data were pooled using the random effects model. Results A total of 1294 articles were screened. Five RCTs were included in the final analysis, enrolling 209 patients with hypertrophic cardiomyopathy (101 patients were in the ARB arm). ARB treatment was not associated with either significant left ventricular mass reduction (standardized mean difference: − 0.25; 95% CI: − 0.73, 0.22; p = 0.29) or change in LVEF (weighted mean difference: 0.73%; 95% CI: − 1.10%, 2.56%; p = 0.43). Subgroup analysis showed that losartan, one of the most investigated and commonly used ARBs, was also not associated with significant decreases of left ventricular mass (standardized mean difference: − 0.13; 95% CI: − 0.61, 0.36; p = 0.61). Conclusion This meta-analysis showed that ARB treatment is not associated with reduced left ventricular mass nor remarkable LVEF change among patients with hypertrophic cardiomyopathy. Further studies with a larger number of patients will be required to confirm these findings.Keywords
This publication has 40 references indexed in Scilit:
- Cardiac fibrosis in mice with hypertrophic cardiomyopathy is mediated by non-myocyte proliferation and requires Tgf-βJCI Insight, 2010
- Comparison of the long-term effects of candesartan and olmesartan on plasma angiotensin II and left ventricular mass index in patients with hypertensionHypertension Research, 2009
- Regression of Left Ventricular Mass by Antihypertensive TreatmentHypertension, 2009
- The Effects of Candesartan on Left Ventricular Hypertrophy and Function in Nonobstructive Hypertrophic Cardiomyopathy: A Pilot, Randomized StudyThe Journal of Molecular Diagnostics, 2009
- Candesartan- and Atenolol-Based Treatments Induce Different Patterns of Carotid Artery and Left Ventricular Remodeling in HypertensionStroke, 2006
- Effect of Losartan on Left Ventricular Diastolic Function in Patients With Nonobstructive Hypertrophic CardiomyopathyThe American Journal of Cardiology, 2005
- Meta-analysis. Update on reversal of left ventricular hypertrophy in essential hypertension (a meta-analysis of all randomized double-blind studies until December 1996)Nephrology Dialysis Transplantation, 1998
- Assessing the quality of reports of randomized clinical trials: Is blinding necessary?Controlled Clinical Trials, 1996
- Echocardiographic assessment of left ventricular hypertrophy: Comparison to necropsy findingsThe American Journal of Cardiology, 1986